Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-199b
- Development stage
- Preclinical
- Lead developer
- Mirabilis Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
anti-miR-199b is an experimental antisense oligonucleotide (antimiR) designed to selectively inhibit microRNA-199b (miR-199b). miR-199b is a microRNA that has been implicated in various pathological processes, including pressure overload-induced cardiac hypertrophy and heart failure, as well as the progression of several malignancies such as acute myeloid leukemia (AML), colorectal cancer, and ovarian cancer. In the heart, miR-199b targets the dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), which normally acts as a negative regulator of the calcineurin/NFAT signaling pathway; thus, inhibiting miR-199b can restore DYRK1A levels and mitigate cardiac remodeling. Additionally, research has explored its role in modulating CD44 expression in lymphocytes to treat experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. Development has been associated with Mirabilis Therapeutics and academic institutions.
- Other names
- miR-199b inhibitormiR199b inhibitormiR 199b inhibitoranti-microRNA-199banti-microRNA199banti-microRNA 199b
Beyond the preview
Go deeper on anti-miR-199b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-199b.